ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

JHVEPhoto/iStock Editorial via Getty Images Since Ani Pharmaceuticals (NASDAQ:ANIP) merged with Biosante Pharmaceuticals in 2013, ANIP's growth has largely been fueled by M&A, the most important of which are the acquisition Purified Cortrophin Gel from Merck & Co., Inc. (MRK) in 2016 and the merger with Novitium Pharma in 2021. The market sees these as drivers of ANIP's growth, and analyst estimates currently reflect this. However, ANIP's royalty revenue potential is largely unnoticed. This article looks at ...